IN8bio CFO granted 75,000 stock options

IN8bio, Inc. (INAB) granted its Chief Financial Officer, McCall Patrick, a new stock option award.

Rhea-AI Filing Summary

IN8bio, Inc. (INAB) granted its Chief Financial Officer, McCall Patrick, a new stock option award. On February 4, 2026, the CFO received an employee stock option to purchase 75,000 shares of common stock at an exercise price of $1.96 per share.

These options were awarded at no cost and are held directly. Twenty-five percent of the shares vest on February 4, 2027, and the remaining shares vest in 36 equal monthly installments afterward, as long as the CFO continues to provide service through each vesting date.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider McCall Patrick

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	75,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 75,000 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IN8bio (INAB) report for its CFO?

IN8bio reported a grant of employee stock options to CFO McCall Patrick. On February 4, 2026, he received options to buy 75,000 shares of common stock at an exercise price of $1.96 per share, held directly as a derivative security.

How many IN8bio (INAB) shares are covered by the CFO’s new stock options?

The new employee stock option grant covers 75,000 shares of IN8bio common stock. Each option allows the CFO to buy one share at $1.96, with all 75,000 options reported as beneficially owned following the transaction and held in direct ownership.

What is the exercise price of the IN8bio (INAB) CFO’s stock option grant?

The CFO’s employee stock option has an exercise price of $1.96 per share. This means he can purchase IN8bio common stock at $1.96 for each of the 75,000 underlying shares, subject to the vesting schedule and continued service conditions described in the filing.

When do the IN8bio (INAB) CFO’s new stock options vest?

Twenty-five percent of the options vest on February 4, 2027. The remaining shares vest in 36 equal monthly installments after that date, provided the CFO continues to provide service through each vesting date, creating a four-year vesting structure starting from grant.

Is the IN8bio (INAB) CFO’s option grant a direct or indirect holding?

The filing shows the CFO’s 75,000 employee stock options as a direct holding. The ownership form is listed as “D” for direct, and no footnotes indicate another entity, so the options are attributed personally to CFO McCall Patrick under the company’s equity compensation arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCall Patrick

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVE. SUITE 5330

(Street)

NEW YORK NY 10118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.96	02/04/2026		A		75,000		(1)	02/04/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attoney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.